Charles Schwab Investment Management Inc. Has $231,000 Position in bluebird bio, Inc. (NASDAQ:BLUE)

Charles Schwab Investment Management Inc. cut its position in shares of bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 27,652 shares of the biotechnology company's stock after selling 525,408 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.28% of bluebird bio worth $231,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of BLUE. BNP Paribas Financial Markets lifted its stake in bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock valued at $193,000 after purchasing an additional 355,562 shares during the last quarter. FMR LLC lifted its position in shares of bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company's stock valued at $1,289,000 after acquiring an additional 186,903 shares during the last quarter. Barclays PLC boosted its stake in shares of bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock worth $130,000 after acquiring an additional 184,605 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company's stock worth $2,433,000 after acquiring an additional 166,771 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the third quarter worth $42,000. Institutional investors own 87.43% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research firms recently weighed in on BLUE. Baird R W lowered bluebird bio from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 21st. Wells Fargo & Company decreased their target price on shares of bluebird bio from $40.00 to $5.00 and set an "equal weight" rating for the company in a report on Monday, February 24th. JPMorgan Chase & Co. upgraded shares of bluebird bio from an "underweight" rating to a "neutral" rating in a report on Monday, February 24th. Barclays decreased their price objective on shares of bluebird bio from $40.00 to $8.00 and set an "overweight" rating for the company in a research note on Monday. Finally, StockNews.com began coverage on shares of bluebird bio in a research note on Friday, March 28th. They set a "sell" rating on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $44.60.

bluebird bio Stock Up 1.2 %

BLUE stock traded up $0.06 during midday trading on Friday, reaching $4.95. The company had a trading volume of 218,770 shares, compared to its average volume of 381,123. The company has a 50 day moving average of $5.29 and a two-hundred day moving average of $7.59. The company has a market capitalization of $48.46 million, a P/E ratio of -0.13 and a beta of 0.41. bluebird bio, Inc. has a 1 year low of $3.56 and a 1 year high of $28.60. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.